Inflammation in prostate cancer progression and therapeutic targeting.
Inflammation in prostate cancer progression and therapeutic targeting.
复制标题
DOI：
10.3978/j.issn.2223-4683.2015.04.12
复制
发表时间：
2015-08
影响因子：
2
通讯作者：
Kyprianou N
中科院分区：
文献类型：
--
作者：
Stark T;Livas L;Kyprianou N
慢性炎症通过重塑细胞外基质（ECM）和启动上皮间质转化（EMT）来改变肿瘤微环境，从而促进人类癌症的发生和进展。在生物学水平上，慢性炎症细胞释放细胞因子，这些细胞因子在功能上决定了组成性活性基质，促进肿瘤生长和转移。在前列腺癌中，炎症与“危险因素”病变或增殖性炎性萎缩（PIA）的发展增加相关。良性前列腺活检标本中的慢性炎症可能与邻近区域的高级别前列腺肿瘤相关。在这篇文章中，我们讨论了目前对前列腺癌进展中炎症发生率的理解，以及该过程在肿瘤进展过程中特异性炎症信号通路和关键效应物的治疗靶向中的意义。进一步了解前列腺肿瘤进展至转移过程中的慢性炎症，将有助于开发和优化治疗晚期疾病高危患者的新型治疗方式。
Chronic inflammation contributes to the onset and progression of human cancer, via modifications in the tumor microenvironment by remodeling the extracellular matrix (ECM) and initiating epithelial mesenchymal transition (EMT). At the biological level, chronically inflamed cells release cytokines that are functionally dictating a constitutively active stroma, promoting tumor growth and metastasis. In prostate cancer, inflammation correlates with increased development of “risk factor” lesions or proliferative inflammatory atrophy (PIA). Chronic inflammation in benign prostate biopsy specimens can be associated with high-grade prostate tumors in adjacent areas. In this article, we discuss the current understanding of the incidence of inflammation in prostate cancer progression and the significance of the process in therapeutic targeting of specific inflammatory signaling pathways and critical effectors during tumor progression. Further understanding of the process of chronic inflammation in prostate tumor progression to metastasis will enable development and optimization of novel therapeutic modalities for the treatment of high-risk patients with advanced disease.